“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

Expanded Approval: Moderna’s mRESVIA vaccine is now FDA-approved for adults aged 18–59 years with an increased risk for respiratory syncytial virus (RSV)-related lower respiratory tract disease.

A study of pediatric outpatient prescriptions over a 10-year period found that flu and respiratory syncytial virus are associated with meaningful proportions of pediatric antibiotic prescribing ...

Respiratory syncytial virus (RSV) is a leading cause of severe respiratory illness and death among children worldwide, particularly in children younger than 6 months and in low-income and ...

Feeling sick in California? How to tell if you have coronavirus, influenza, respiratory syncytial virus or norovirus and prevent illness.

Human metapneumovirus (HMPV) is a respiratory virus causing increasing concern globally, with recent spikes in cases in China. Antibiotics are ineffective against HMPV as it is a virus, not a ...

Learn why antibiotics are not effective against influenza, and what better options exist for preventing and treating the flu.

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons ...